Immunologic analysis by spectral flow cytometry and clinical correlation. (A) Panel depicts CD8⁺ (left) and CD4⁺ (right) T-cell subset changes, respectively, at various timepoints from screening to month 12 after CTL019 infusion and compared with healthy donors (n = 16). (B) Panel shows a comparison between the absolute lymphocyte count (left) and percentage of NK cells as a proportion of mononuclear cells (right) at screening in patients exposed and those not exposed to bendamustine. (C) Panel depicts a comparison of CD8⁺/HLA^–DR^–/PD-1⁺ TEMRAs as a proportion of T cells at various timepoints (left) and preleukapheresis (right) in deep responders vs all other patients. Deep responder was defined as a patient with negative MRD by flow cytometry at month 4. NK cells, natural killer cells; Tcm, T central memory cells; Tem, T effector memory cells; TEMRAs, terminally differentiated effector memory cells (CD45RA⁺).